Coronary/Structural Heart

Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months

WASHINGTON–(BUSINESS WIRE)–Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study evaluating the safety and performance of its LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) for the treatment of moderate to severely calcified coronary artery lesions demonstrating safety […]

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading cardiovascular digital health company, today announced the results of its seminal research on the real-world impact of clinical presentation among patients with moderate or greater aortic stenosis (AS) undergoing aortic valve replacement (AVR). Presented by Philippe Généreux, MD, Director of the Structural Heart […]

Cardiawave Announces Positive Six-Month Data from Valvosoft Pivotal Study at Transcatheter Cardiovascular Therapeutics (TCT) Conference

WASHINGTON–(BUSINESS WIRE)–Cardiawave SA, developer of the groundbreaking Valvosoft Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis (CAS), today announced that the device met the primary endpoint in its pivotal study and improved or stabilized heart failure symptoms for 80.5% of patients, substantially improving hemodynamics […]

Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device

GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE PATCH Pivotal Study evaluating the safety and efficacy of the Vivasure PerQseal® Closure Device System, at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 annual conference in Washington, D.C. […]

The 21st World Congress of Chinese Medicine – Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

PAIRS, Oct. 28, 2024 /PRNewswire/ — On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the…

Cardiosense Presents Interim Clinical Study Data for Machine Learning Algorithm to Aid in Heart Failure Management at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 Scientific Symposium

CHICAGO, Oct. 28, 2024 /PRNewswire/ — Cardiosense, a digital health company developing heart failure management platforms for the early detection of worsening heart failure, today presented clinical data at the Cardiovascular Research Foundation’s 2024 annual Transcatheter Cardiovascular…

MitrAssist Lifesciences Announces Promising Initial Clinical Results for SIKELIA™ Polymeric Heart Valve at TCT Conference 2024

WASHINGTON, Oct. 28, 2024 /PRNewswire/ — MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIA™, during the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference…

HeartFocus Unveils AI-powered Education App for Conducting Clinical-Grade Heart Scans, Available on Butterfly Network’s Handheld Ultrasound Devices

BORDEAUX, France–(BUSINESS WIRE)–HeartFocus, the revolutionary, AI-enabled heart echo software by data-driven medtech company, DESKi, is proud to announce the launch of the HeartFocus Education app in partnership with Butterfly Network, Inc., (“Butterfly”) (NYSE: BFLY) a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software. The innovative HeartFocus […]

Groundbreaking Data Demonstrate Superiority of EARLY TAVR in Asymptomatic Severe Aortic Stenosis Patients

WASHINGTON–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe […]

Cleerly Secures CPT Category I Code for AI-QCT Advanced Plaque Analyses

October 28, 2024 (DENVER) – Cleerly, a pioneer in advanced cardiovascular imaging, is thrilled to announce that the American Medical Association (AMA) has approved a CPT Category I code for its AI-QCT advanced plaque analyses. This significant milestone, set to take effect January 1, 2026, marks a transformative step in […]